De-extinction is a commercially viable enterprise that can be funded by ecosystem restoration, certified nature credits, and ecotourism, with the potential for billions in annual revenue.
Advanced genetic engineering, specifically high-plex multiplex editing, is the core technological platform that enables both de-extinction and valuable spin-off applications in human health and industrial processes.
The restoration of keystone species like the woolly mammoth and forest elephants provides quantifiable, massive economic and ecological value, justifying the significant investment in their return.
Technological development for de-extinction, such as artificial wombs and 'universal eggs', will create breakthrough innovations with significant applications in other scientific fields, including human mitochondrial health.
There are clear ethical boundaries for genetic engineering; Colossal's company policy explicitly prohibits any work on humans, human precursors, or non-human primates.
Pre-2021
George Church's foundational mammoth de-extinction research at Harvard University is supported by a $100,000 donation from Peter Thiel, stretched over a 10-year period.
2021
Ben Lamm founds Colossal, a de-extinction and species preservation company, to scale and commercialize the technology.
2021-Present
Colossal raises a total of $435 million for the company and an additional $50 million for its associated foundation from a diverse investor base including the U.S. intelligence community.
Recent
Lamm reports major technological breakthroughs, including the ability to perform over 50 simultaneous genetic edits and the first successful insertion of ancient DNA into a living species with 100% efficiency.
Recent
Colossal announces the creation of dire wolf proxies and the successful cloning of four critically endangered red wolves, demonstrating the application of its technology to both de-extinction and conservation.
Recent
The company spins out three separate ventures: a computational biology platform, a plastic degradation company called Breaking, and an unannounced company valued at over $100 million.
▶Pioneering Genetic Engineering as a Platform TechnologyApr 2026
Lamm positions Colossal not just as a de-extinction company, but as a leader in foundational genetic technologies. He highlights breakthroughs like making over 50 simultaneous gene edits, developing AI for optimizing edits, and creating novel cloning methods, which are then spun out into separate ventures for human healthcare and industrial use.
Investors should view Colossal less as a 'zoo' company and more as a high-risk, high-reward biotech platform whose core value lies in its intellectual property in gene editing and computational biology, with de-extinction serving as a powerful proof-of-concept and public-facing mission.
▶Monetizing Ecosystem Restoration
Lamm outlines a long-term business model that moves beyond venture capital to recurring revenue from environmental services. He argues that reintroducing keystone species like mammoths generates quantifiable value through ecosystem stability, which can be sold as 'certified nature credits' to nations and corporations, supplemented by ecotourism revenue.
The viability of Lamm's long-term vision is heavily dependent on the maturation and professionalization of the biodiversity credit markets, which are still nascent but attracting institutional players like TPG and Lloyd's of London.
▶De-extinction as a Scientific CatalystApr 2026
The ambitious goals of resurrecting species like the woolly mammoth serve as drivers for fundamental scientific research. Lamm details the complex challenges, such as requiring 85 gene edits for a mammoth proxy or developing artificial wombs, which force his team of 140 scientists to innovate in areas like stem cell biology and interspecies surrogacy.
The de-extinction projects act as 'moonshots' that accelerate the development of tools and knowledge, such as the 'universal egg' concept, which could have significant, unforeseen applications in other fields like mitochondrial health.
▶Bridging Conservation and Commercialization
Lamm presents a narrative where commercial incentives are aligned with conservation goals. He points to the successful cloning of four critically endangered red wolves using technology developed for the dire wolf project and the fight against the EEHV virus in elephants as examples of how Colossal's work directly aids current biodiversity crises.
This dual-mission approach allows the company to attract a wider range of capital, including from foundations and governments, and build public goodwill, mitigating some of the ethical and reputational risks associated with the more controversial de-extinction work.